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Inclusion and exclusion criteria in full
Patients were eligible for the trial if aged 18-70 with compensated cirrhosis and a Model for End-stage Liver Disease (MELD) score greater than or equal to 11.5 and less than 15.5. The specific inclusion criteria are listed below. In addition to the general exclusion criteria there were specific exclusion criteria related to liver disease and to the safety of GCSF administration, which are listed below. 
Inclusion Criteria

Trial schedule and data collection
1 For patients in arms 1 and 2 Visit 1 and visit 2a should be combined into one day where possible. For patients in arm 3, timing of visit 2a will depend on scheduling of leukapheresis.
2 All screening tests must be completed less than 7 days prior to randomisation and treatment and must start less than 7 days following randomisation. Day of randomisation will be considered as Day 1 for scheduling purposes.
3 Clinical assessment consists of complete history and examination at screening and focussed history and relevant examination at subsequent visits.
4 Vital Signs to include heart rate, blood pressure, temperature and weight. 5 Screening blood tests as detailed in protocol
Additional analysis -statistical methodology
A model incorporating splines was constructed to assess fit. Model selection was then performed beginning with a mixed-model including just treatment arm (factor) and time (continuous) covariates, and then by iteratively increasing flexibility as required to find the most parsimonious model resulting in approximately optimum fit; polynomial, interaction, and change-point terms were all explored in doing so.
The study was designed to detected differences in primary 1 only and not to detect differences in trend or interactions, which was proposed in order to explore the change in longitudinal outcome measures over the study period. As such, less emphasis is placed upon p values for co-primary 2; rather a focus on magnitude of trend.
Co-primary 2 results
What follows describes the results of the final mixed effects model with a change-point for co-primary 2. Note that in a departure from the convention adopted thus far in this supplement rate of change is described in per week since resulting estimates are more tangible in the context of generally small changes.
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• Y "# is the MELD score for patient < with four planned measurements at time points = at 0 and approximately 4.3, 8.6 and 12.9 weeks (corresponding to visit days 30, 60 and 90) • m +" and m ," are dummy variables for treatment groups 2 and 3 respectively • t "# is time (in weeks) ranging from 0 to 12.9 weeks (90 days) for patient < • t "#) = t "# − 4.3, t "# for B 0, 4.3 , and 0 otherwise, and represents up to 4.3 weeks The continuous time-scale, representing timing of measurement, was split at 4.3 weeks (30 days) allowing differing trends to be explored both prior to and after this point, hereafter referred to as period 1 and 2 respectively. Splits at 8.6 weeks, and +/-5 days either side of the particular change-point were also explored but found to fit the data less well. The model also incorporates interactions between time period and group, to allow for the rate of change to differ between groups.
The estimated coefficients of time for period 1 (-0.043) and period 2 (0.005) can be considered the average rate of change in MELD (per week) in group 1, and indicate a small reduction in MELD in period 1, and an approximately constant thereafter. In neither case was there evidence that the rates differed from zero (p=0. 64 and 0. 91 respectively). Interaction terms estimated the difference in rate of change for each treatment group relative to group 1. In period 1 the group 2 and 3 interaction estimates of 0.14 (p=0. 28) and 0.022 (p=0. 87) were not found to differ from zero, and hence there was no evidence that the rates of change differed from group 1. When combined (additively) with corresponding time estimates, the interaction terms for period 1 can be interpreted on average as an increment of 0.093 for group 2, and a decrement of -0.021 for group 3 for each unit increase in time, i.e. a week.
Similarly, there was no evidence of non-zero estimates in period 2, with group 2 and 3 with interaction coefficients -0.066 (p=0.31) and -0.005 (p=0. 94) respectively. In combination the estimates indicated a weekly decrement of 0.071 for group 2, and an approximately zero change for group 3. Hence there was no evidence that the rates in period 2 differed from group 1. Furthermore, testing for a change-point indicated that the trends do not differ between periods with p=0.76. Of note the corresponding model term does not belong to the final model described in the foregoing. Legend for table S1: Mixed model for MELD over 4.3 weeks (90 days). Incorporates change point at 4.3 weeks (day 30), and allows for changes in trend to differ between groups before and after change-point.
An unplanned analyses explored the impact of alcohol history on change in MELD score. The final MELD mixed model was adjusted for 'ever' versus 'never' drinkers, and the final model was also fitted in only those patients that had ever drank, with adjustment for length of abstinence.
Results
There was no evidence that having previously consumed alcohol affected MELD (p=0.26) (Appendix Table   S2 ). Nor was there evidence that length of abstinence in those patients that had consumed alcohol had any impact on MELD (p=0.41) (Appendix Table S3 ). Legend for Table S2 : final mixed model adjusted for alcohol consumption. With parameters as before and with β 9 the coefficient for 'having consumed alcohol (versus not). Legend for Table S3 : final mixed model adjusted for length of abstinence. With parameters as before and with β 9 the coefficient for length of abstinence in months. Legend for table S4: final mixed model aetiology. With parameters as before and with β 9 and β 10 the respective coefficients of aetiology levels (versus alcohol related). Legend for Table S6 : Cell counts in the apheresis product and after the MACS selection are expressed as medians (IQR). The percentage recovery of cells is detailed in the final column. Liver disease severity Legend for Table S7 : Change in MELD and UKELD from baseline to D180 and D360
MELD
The table summarises changes in baseline characteristics from day zero to day 180 and day 360. Values presented are delta of medians (IQR). Statistical comparison was made between change at day 180 and 360 to baseline between treatment and control arms -there were no significant differences. Hepatobiliary disorders 2 ( 7.1%) 1 ( 3.6%) 0 (0%) 0 (0%) 1 ( 3.7%) 1 ( 3.7%) 0 (0%) 0 (0%) 6 (23.1%) 0 (0%) 0 (0%) 0 (0%) Cardiac disorders -0 (0%) 0 (0%) 0 (0%) -0 (0%) 0 (0%) 0 (0%) -1 ( 3.8%) 0 (0%) 1 ( 3.8%)
Renal and urinary disorders -0 (0%) 0 (0%) 0 (0%) -1 ( 3.7%) 0 (0%) 0 (0%) -1 ( 3.8%) 0 (0%) 0 (0%) Vascular disorders -0 (0%) 0 (0%) 0 (0%) -0 (0%) 0 (0%) 0 (0%) -1 ( 3.8%) 0 (0%) 0 (0%) Surgical and medical procedures -2 ( 7.1%) 0 (0%) 0 (0%) -1 ( 3.7%) 0 (0%) 0 (0%) -0 (0%) 0 (0%) 0 (0%)
Legend for Table S8 : This table details worst-grade adverse events at the patient level and by CTC category. For grades 1 and 2, the CTC categories reported are those in which 10% or more of patients experienced grade of 1 or 2 at worst. All CTC categories with grades of 3 and above are reported.. The Gastrointestinal adverse events included symptoms such as abdominal pain, ascites, bloating, constipation, diarrhoea, dyspepsia, nausea and vomiting. Musculoskeletal and connective tissue disorders consisted of arthralgia, back pain, generalised muscle weakness, myalgia and pain in extremity. Nervous system disorders consisted of amnesia, dizziness, encephalopathy, headache, lethargy, peripheral neuropathy, syncope and tremor.
